409 related articles for article (PubMed ID: 19106034)
1. Neuroleptic effects on P50 sensory gating in patients with first-episode never-medicated schizophrenia.
Hong X; Chan RC; Zhuang X; Jiang T; Wan X; Wang J; Xiao B; Zhou H; Jiang L; Weng B
Schizophr Res; 2009 Mar; 108(1-3):151-7. PubMed ID: 19106034
[TBL] [Abstract][Full Text] [Related]
2. Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients.
Adler LE; Olincy A; Cawthra EM; McRae KA; Harris JG; Nagamoto HT; Waldo MC; Hall MH; Bowles A; Woodward L; Ross RG; Freedman R
Am J Psychiatry; 2004 Oct; 161(10):1822-8. PubMed ID: 15465979
[TBL] [Abstract][Full Text] [Related]
3. Antipsychotic effects on auditory sensory gating in schizophrenia patients.
Sánchez-Morla EM; Santos JL; Aparicio A; García-Jiménez MA; Villanueva C; Martínez-Vizcaíno V; Arango C
Eur Neuropsychopharmacol; 2009 Dec; 19(12):905-9. PubMed ID: 19833483
[TBL] [Abstract][Full Text] [Related]
4. P50 gating at acute and post-acute phases of first-episode schizophrenia.
Devrim-Uçok M; Keskin-Ergen HY; Uçok A
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1952-6. PubMed ID: 18929611
[TBL] [Abstract][Full Text] [Related]
5. Sensory-gating deficit of the N100 mid-latency auditory evoked potential in medicated schizophrenia patients.
Boutros NN; Brockhaus-Dumke A; Gjini K; Vedeniapin A; Elfakhani M; Burroughs S; Keshavan M
Schizophr Res; 2009 Sep; 113(2-3):339-46. PubMed ID: 19524407
[TBL] [Abstract][Full Text] [Related]
6. P50 suppression and its neural generators in antipsychotic-naive first-episode schizophrenia before and after 6 months of quetiapine treatment.
Oranje B; Aggernaes B; Rasmussen H; Ebdrup BH; Glenthøj BY
Schizophr Bull; 2013 Mar; 39(2):472-80. PubMed ID: 22241164
[TBL] [Abstract][Full Text] [Related]
7. Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications.
Light GA; Geyer MA; Clementz BA; Cadenhead KS; Braff DL
Am J Psychiatry; 2000 May; 157(5):767-71. PubMed ID: 10784470
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of adenosine A2A receptors induced by atypical antipsychotics and its correlation with sensory gating in schizophrenia patients.
Zhang J; Abdallah CG; Wang J; Wan X; Liang C; Jiang L; Liu Y; Huang H; Hong X; Huang Q; Wu R; Xu C
Psychiatry Res; 2012 Dec; 200(2-3):126-32. PubMed ID: 22705363
[TBL] [Abstract][Full Text] [Related]
9. P50 gating in deficit and nondeficit schizophrenia.
Santos JL; Sánchez-Morla EM; Aparicio A; García-Jiménez MA; Villanueva C; Martínez-Vizcaíno V; Arango C
Schizophr Res; 2010 Jun; 119(1-3):183-90. PubMed ID: 20153607
[TBL] [Abstract][Full Text] [Related]
10. Differential sensory gating functions between smokers and non-smokers among drug-naive first episode schizophrenic patients.
Chen XS; Li CB; Smith RC; Xiao ZP; Wang JJ
Psychiatry Res; 2011 Aug; 188(3):327-33. PubMed ID: 21216472
[TBL] [Abstract][Full Text] [Related]
11. [The follow-up study on P50 auditory sensory gating in naïve schizophrenia].
Wang HX; Zhang MD; Wang ZC; Chen XS; Lou FY; Liang JH; Chen C
Zhonghua Yi Xue Za Zhi; 2010 Mar; 90(9):601-5. PubMed ID: 20450782
[TBL] [Abstract][Full Text] [Related]
12. Gating of auditory P50 in schizophrenics: unique effects of clozapine.
Nagamoto HT; Adler LE; Hea RA; Griffith JM; McRae KA; Freedman R
Biol Psychiatry; 1996 Aug; 40(3):181-8. PubMed ID: 8830951
[TBL] [Abstract][Full Text] [Related]
13. A follow-up study on features of sensory gating P50 in treatment-resistant depression patients.
Wang Y; Fang YR; Chen XS; Chen J; Wu ZG; Yuan CM; Yi ZH; Hong W; Zhang C; Cao L
Chin Med J (Engl); 2009 Dec; 122(24):2956-60. PubMed ID: 20137481
[TBL] [Abstract][Full Text] [Related]
14. Auditory verbal hallucinations in schizophrenia correlate with P50 gating.
Smith DM; Grant B; Fisher DJ; Borracci G; Labelle A; Knott VJ
Clin Neurophysiol; 2013 Jul; 124(7):1329-35. PubMed ID: 23490551
[TBL] [Abstract][Full Text] [Related]
15. Sensory gating in schizophrenia: P50 and N100 gating in antipsychotic-free subjects at risk, first-episode, and chronic patients.
Brockhaus-Dumke A; Schultze-Lutter F; Mueller R; Tendolkar I; Bechdolf A; Pukrop R; Klosterkoetter J; Ruhrmann S
Biol Psychiatry; 2008 Sep; 64(5):376-84. PubMed ID: 18395700
[TBL] [Abstract][Full Text] [Related]
16. Dopaminergic modulation of the P50 auditory-evoked potential in a computer model of the CA3 region of the hippocampus: its relationship to sensory gating in schizophrenia.
Moxon KA; Gerhardt GA; Adler LE
Biol Cybern; 2003 Apr; 88(4):265-75. PubMed ID: 12690485
[TBL] [Abstract][Full Text] [Related]
17. Chronic effects of cannabis on sensory gating.
Broyd SJ; Greenwood LM; Croft RJ; Dalecki A; Todd J; Michie PT; Johnstone SJ; Solowij N
Int J Psychophysiol; 2013 Sep; 89(3):381-9. PubMed ID: 23628289
[TBL] [Abstract][Full Text] [Related]
18. Improved p50 auditory gating with ondansetron in medicated schizophrenia patients.
Adler LE; Cawthra EM; Donovan KA; Harris JG; Nagamoto HT; Olincy A; Waldo MC
Am J Psychiatry; 2005 Feb; 162(2):386-8. PubMed ID: 15677607
[TBL] [Abstract][Full Text] [Related]
19. Baseline dependency of nicotine's sensory gating actions: similarities and differences in low, medium and high P50 suppressors.
Knott V; de la Salle S; Smith D; Phillipe T; Dort H; Choueiry J; Impey D
J Psychopharmacol; 2013 Sep; 27(9):790-800. PubMed ID: 23744798
[TBL] [Abstract][Full Text] [Related]
20. P50 inhibition defects with psychopathology and cognitive impairment in patients with first-episode drug naïve schizophrenia.
Xia L; Wang D; Wei G; Wang J; Zhou H; Xu H; Tian Y; Dai Q; Xiu M; Chen D; Wang L; Zhang X
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Apr; 107():110246. PubMed ID: 33453321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
